News
FDA declares an end to tirzepatide shortage, the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro.
MSD partners LaNova Medicines on a PD-1 and VEGF targeting candidate for cancer, a potential replacement for its top-seller Keytruda.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback